Normal human immunoglobulins for intravenous use (IVIg) delay hyperacute xenograft rejection through F(ab')2-mediated anti-complement activity.
Xenotransplantation between discordant species leads to a hyperacute rejection mediated by natural antibodies, both of the IgG and IgM isotypes, activation of complement and endothelial cell activation. The combination of these mechanisms leads to a transplant survival of minutes to a few hours. Polyclonal human immunoglobulins for intravenous use (IVIg) from normal donors have proved effective in a number of antibody-mediated disorders, as well as in inflammatory disorders. We demonstrate that administration of IVIg in a guinea pig to rat model of cardiac xenografting can effectively delay hyperacute rejection. This effect is mediated by the F(ab')2 fragments of IVIg, and is correlated to an anti-complementary activity.
Latremouille
C
C
INSERM U 430, Hôpital Broussais, Paris, France.
Genevaz
D
D
Hu
M C
MC
Schussler
O
O
Goussef
N
N
Mandet
C
C
Bruneval
P
P
Haeffner-Cavaillon
N
N
Carpentier
A
A
Glotz
D
D
D000208:Acute Disease; D000818:Animals; D003167:Complement Activation; D005260:Female; D006084:Graft Rejection / Q000276:immunology* / Q000517:prevention & control*; D006168:Guinea Pigs; D016027:Heart Transplantation; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000276:immunology*; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D008297:Male; D051381:Rats; D011917:Rats, Inbred Lew; D014183:Transplantation, Heterologous
D007140:Immunoglobulin Fab Fragments; D016756:Immunoglobulins, Intravenous